Table 3.
Efficacy of targeted therapy against HER2
| First author | Year | Treatment modality | QT added | Effect | Line of treatment | PFS, months | OS, months |
|---|---|---|---|---|---|---|---|
| Karam [104] | 2008 | Trastuzumab (300 mg/m2) | PR | First line | 12 | NR | |
| Takahagi [105] | 2009 | Trastuzumab 2 mg/kg qw (LD 4 mg/kg) | Paclitaxel (80 mg/m2 qw)a | PR | First line | 6 | 15 |
| Hanawa [106] | 2011 | Trastuzumab 2 mg/kg (LD 4 mg/kg), 6 weeks on/2 weeks off | Paclitaxel (80 mg/m2 qw)b | PR | First line | 14 | NR |
| Wakabayashi [107] | 2012 | Trastuzumab 6 mg/kg q3w (LD 8 mg/kg) | CR | First line | >13 | NR | |
| Yoshimura [108] | 2013 | Trastuzumab 2 mg/kg qw (LD 4 mg/kg) | Paclitaxel | NR | Second line | 4 | 14 |
| Barth [109] | 2015 | Trastuzumab 6 mg/kg q3w (LD 8 mg/kg) | CR | First line | >12 | NR | |
| Zhang [110] | 2015 | Trastuzumab 6 mg/kg q3w | PR | Second line | >11 | NR | |
| Shin [111] | 2016 | Lapatinibc | Capecitabined | NR | Second line | NR | NR |
| T-DM1c | CR | Third line | 12 | ||||
| Watanabe [112] | 2016 | Trastuzumab 6 mg/kg q3w (LD 8 mg/kg)e | PR | First line | 5 | >17 | |
| Trastuzumab 6 mg/kg (LD 8 mg/kg) and pertuzumab 420 mg/m2 (LD 840 mg/m2) q3we | Docetaxel (75 mg/m2 q3w) | PR | Second Line | 12 | |||
| Ichiyama [113] | 2017 | Trastuzumab 2 mg/kg qw (LD 4 mg/kg) | Paclitaxel (80 mg/m2 qw) | PR | First line | >30 | NR |
| Lu [103••] | 2019 | Trastuzumab 2 mg/kg qw | Paclitaxel (80 mg/m2) and cisplatin (30 mg/m2) qw | CR | First line | 17 | NR |
| Trastuzumab 360 mg q3wf | Paclitaxel (80 mg/m2 qw) | SD | Second line | 5 | NR | ||
| Lapatinibf | Capecitabine | SD | Third line | 5 | |||
| Sekiguchi [114•] | 2020 | Trastuzumab 2 mg/kg qw | Paclitaxel 80 mg/m2 qw | PR | First line | 12 | 30 |
| Trastuzumab 2 mg/kg qw | Paclitaxel 80 mg/m2 qw | PD | First line | 2 | 6 | ||
| Trastuzumab 2 mg/kg qw | Paclitaxel 80 mg/m2 qw | PD | First line | 4 | 13 | ||
| Trastuzumab 2 mg/kg qw | Paclitaxel 80 mg/m2 qw | PD | First line | 3 | 20 | ||
| Kimura [115] | 2020 | Trastuzumab (biosimilar) 2 mg/kg q2w | SD | Second line | >6 | 13 |
QT, chemotherapy; PFS, progression free survival; OS, overall survival; LD, loaded dose; qm, once a month; qw, once a week; q3w, once every 3 weeks; NR, not reported; CR, complete response; PR, partial response; SD, stable disease
aIn the first cycle, chemotherapeutic agent was docetaxel. Paclitaxel was added because there was no response with docetaxel
bPaclitaxel was added in the second cycle, because there was no response
cThese regimens belong to the same patient
dAdded when lapatinib dose was reduced because hepatic toxicity
eThese regimens belong to the same patient
fThese regimens belong to the same patient